Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Any patient undergoing elective hand surgery~Exclusion Criteria:~* Any patient with a traumatic open wound (only surgically created wounds will be included)~* History of chronic pain~* History of narcotic addiction~* History of recreational drug dependency~* History of psychiatric pathology~* Allergy to local anesthetics, recombinant human thrombin or tranexamic acid~* Any patient receiving a supra/infraclavicular block for anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Topical lidocaine and bupivacaine alone (Type: EXPERIMENTAL): In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine
- Topical lidocaine and bupivacaine with thrombin (Type: EXPERIMENTAL): In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin
- Topical lidocaine and bupivacaine with thrombin and tranexamic acid (Type: EXPERIMENTAL): In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid
- Topical lidocaine and bupivacaine with thrombin and aminocaproic acid (Type: EXPERIMENTAL): In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).